Şizofreni ve diyabet: Yeni kuşak antipsikotiklerin yol açtığı diyabet veya metabolik sendrom

metin, özmen; BİRSÖZ, Sunar; USTA, Evrim

Şizofreni ve diyabet: Yeni kuşak antipsikotiklerin yol açtığı diyabet veya metabolik sendrom

Evrim USTA, (Akdeniz Üniversitesi, Tıp Fakültesi, Psikiyatri Anabilim Dalı, Antalya, Türkiye)

Özmen METİN, (Akdeniz Üniversitesi, Tıp Fakültesi, Psikiyatri Anabilim Dalı, Antalya, Türkiye)

Sunar BİRSÖZ (Akdeniz Üniversitesi, Tıp Fakültesi, Psikiyatri Anabilim Dalı, Antalya, Türkiye)

Klinik Psikofarmakoloji Bülteni

38 2

Yıl: 2007 Cilt: 17 Sayı: 4 Sayfa Aralığı: 207 - 216 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Şizofreni ve diyabet: Yeni kuşak antipsikotiklerin yol açtığı diyabet veya metabolik sendrom

Öz:

Diyabet, insülin aktivitesinde ve/veya insülin üretiminde bozukluk olması nedeniyle kan glikoz seviyelerinin yüksek seyrettiği kronik bir hastalıktır. Bu metabolik bozukluk, çeşitli komplikasyonların sonucu olarak birçok organ sistemini hasara uğratır, yaşam kalitesini kötüleştirir ve yaşam süresini kısaltır. Şizofreni hastalarında diyabet yaygınlığının genel nüfusa göre 2–4 kat daha fazla olduğu bildirilmiştir. Şizofrenide olduğu gibi şizoafektif bozukluk, bipolar bozukluk ve majör depresyon gibi diğer bazı psikiyatrik bozukluklarda da artmış diyabet yaygınlığından bahsedilmiştir. Bununla beraber son yıllarda özellikle şizofreni hastalarında yeni kuşak antipsikotik ilaçların yaygın olarak kullanılmasıyla, araştırmacılar, şizofreni hastalarında diyabet yaygınlığının arttığını veya hastaların glikoz ve/veya lipid metabolizmalarının kötüleştiğini bildirmişlerdir. Bu bildirimler araştırmacıları, şizofreni ile diyabet birlikteliğinin nedenlerini açıklamaya yöneltmiştir. Klinisyenler, şizofreni hastalarında diyabet gelişimi yanında metabolik sendrom gelişimi konusunda da dikkatli olmalıdırlar. Metabolik sendrom ölçütlerini karşılayan diyabetik olmayan hastalar, kardiyovasküler hastalık ve diyabet gelişimi için yüksek risk grubundadırlar. Yeni kuşak antipsikotik ilaç alan hastalarda metabolik yönden izlem yapılması, metabolik sendromun veya diyabetin tanısını kolaylaştıracaktır ve erken tedavi, hastaların yaşam kalitesini arttıracak ve yaşam süresini uzatacaktır. Bu yazıda, şizofreni ile diyabet birlikteliğinin olası nedenleri ile beraber yeni kuşak antipsikotiklerin yol açtığı diyabet veya metabolik sendrom konuları gözden geçirilecektir.

Anahtar Kelime: Diabetes mellitus Şizofreni Antipsikotik ajanlar Metabolik sendrom X Yan etkiler İlaç toksisitesi

Konular: Psikiyatri

Schizophrenia and diabetes mellitus: Diabetes mellitus or metabolic syndrome caused by new generation antipsychotics

Öz:

Diabetes mellitus is a chronic disease in which blood glucose levels are continuously high because of the defects in insulin activity and/or insulin production. This metabolic disorder harms many organ systems, worsens quality of life and shortens lifetime as a result of various complications. The prevalence of type II diabetes mellitus in patients with schizophrenia has been reported to be two or four times greater than in general population. Besides schizophrenia an elevated prevalence of diabetes mellitus has been reported in several other psychiatric disorders such as schizoaffective disorder, bipolar disorder and major depression. However, with wide spread use of new generation antipsychotics in recent years particularly in the treatment of patients with schizophrenia researchers reported that prevalence of type II diabetes mellitus in these patients has been increased or patients’ glucose and/or lipid profiles have been worsened. These reports have led researchers to explain the reasons of association between schizophrenia and diabetes mellitus. Clinicians should be aware of the development of metabolic syndrome as well as of diabetes mellitus in patients with schizophrenia. Nondiabetic patients who meet criteria for the metabolic syndrome represent a high risk group for cardiovascular disease and development of type II diabetes mellitus. Metabolic monitoring of patients that receiving new generation antipsychotic medication will facilitate to diagnose metabolic syndrome or diabetes mellitus and an early treatment will increase the quality of life and the lifetime of the patients. In this paper, the probable reasons of the association between schizophrenia and diabetes mellitus will be reviewed together with the diabetes mellitus or metabolic syndrome caused by the new generation antipsychotics.

Anahtar Kelime: Metabolic Syndrome X Adverse effects Drug Toxicity Diabetes Mellitus Schizophrenia Antipsychotic Agents

Konular: Psikiyatri

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Sadock BJ, Sadock VA. Endocrine and Metabolic Disorders, Diabetes Mellitus, Kaplan and Sadock's Comprehensive Textbook of Psychiatry, Eighth edition, Volume two, 2004; 2161-2162
2. Charbonnel B. What a psychiatrist needs to know about diabetes, Eur Psychiatry, 2005; 20: 330-334
3. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB,Chakos M, Lieberman JA.. Changes in glucose and cholesterol levels inpatients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290-296
4. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Comp Psychiatry 1996; 37: 68-73
5. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, Lehman A.. Prevelance on correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26: 903-912
6. F Casadebaig , A Philippe, J.M. Guillaud-Bataille, M.F. Gausset, N Quemada and J.L. Terra. Schizophrenic patients: physical health and access to somatic care. Eur Psychiatry 1997; 12: 289-293
7. Subramaniam M, Chong SA, Pek E.. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 2003; 48: 345-347
8.Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerancein first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160(2): 284-289 .
9. Thomas P, Raymondet P, Charbonnel B, Vaiva G. Are the specific care requirements for patients with schizoprenia and diabetes or with a risk of diabetes? Eur Psychiatry 2005; 20: 358-363
10. Rouillon F, Sorbara F. Schizoprenia and diabetes: epidemiological data, Eur Psychiatry 2005; 20: 345-348
11. Bellivier F. Schizoprenia, antipsychotics and diabetes: genetic aspects, Eur Psychiatry 2005; 20: 335-339
12. Che_a D, Dumitrescu C, Georgescu M, Cocioab_ G, Lichiardopol R, Stamoran MJonescu-Tfrgovişte C, P_unescu-Georgescu M, Mincu I.. A study on the types of diabetes mellitus in firstdegree relatives of diabetic patients. Diabete Metab 1990; 16:11-15
13. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. increase prevalence type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorder independent of psychotropic drug use. J Affect Disord 2002; 70: 19-26
14. McGuffin P, Tandon K, Corsico A. Lineage and association studies of schizoprenia. Curr Psychiatry Rep 2003; 121-127
15. Wolford JK, Gruber JD, Ossowski VM, Vozarova B, Antonio Tataranni P, Bogardus QHanson RL.. A C-reactive protein promoter polymorphisms associated with type 2 diabetes mellitus in Pima Indians. Mol Genet Metab 2003; 78:136-144
16. Wolford JK, Konheim YL, Colligan PB, Bogardus C.Association of a F479L variant in the cytosolic phospholipase A2 gene (PLA2G4A) with decreased glucose turnover and oxidation rates in Pima Indians. Mol Genet Metab 2003; 79: 61-66
17. Hager J, Dina C, Francke S, Dubois S, Houari M, Vatin V, Vaillant E, Lorentz N,Basdevant A, Clement K, Guy-Grand B, Froguel P.. A genomewide sean for human obesity genes reveals a major susceptibility locus on chromosome 10. Nat Genet 1998; 20: 304-308
18. Mitchell BD, Cole SA, Hsueh WC, Comuzzie AG, Blangero J, MacCluerJW, Hixson JE.Linkage of serum insulin concentrations to chromosome 3p in Mexican Americans. Diabetes 2000; 49: 513-516
19. Collier DA, Barrett TG, Curtis D, Macleod A, Arranz MJ, Maassen JA, Bundey S.Liiikage of Wolfram syndrome to chromosome 4p16.1 and evidence for heterogeneity. Am J Hum Genet 1996; 59: 855-863
20. Blasi C, Pierelli F, Rispoli E, Saponara M, Vingolo E, Andrearii D. Wolfram's syndrome: a clinical, diagnostic, and interpretativecontribution. Diabetes Care 1986; 9: 521-528
21. Inoue H, Tanizawa Y, Wasson J, Behn P, Kalidas K, Bernal- Mizrachi E, Mueckler M,Marshall H, Donis-Keller H, Crock P, Rogers D, Mikuni M, Kumashiro H, Higashi K,Sobue G, Oka Y, Permutt MA. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet 1998; 20:143-148
22. Evans KL, Lawson D, Meitinger T, Blackwood DH, Porteous DJ.. Mutational analysis of the Wolfram syndrome gene in two families with chromosome 4p-linked bipolar affective disorder. Am J Med Genet 2000; 96:158-160
23. Torres R, Leroy E, Hu X, Katrivanou A, Gourzis P, Papachatzopoulou A, Athanassiadou A, Beratis S, Collier D, Polymeropoulos MH.Mutation screening of the Wolfram sendrome gene in psychiatric patients. Mol Psychiatry 2001; 6: 39-43
24. Eubanks JH, Altherr M, Wagner-McPherson C, McPherson JD, Wasmuth JJ, Evans GA.Localization of the D5 dopamine receptor gene to human chromosome 4pl5.1-pl5.3, centromeric to the Huntington' s disease locus. Genomics 1992; 12: 510-516
25. Chiba M, Suzuki S, Hinokio Y, Hirai M, Satoh Y, Tashiro A, Utsumi A, Awata T,Hongo M, Toyota T.Tyrosine hydroxylase gene microsatellite polymorphism associated with insulin resistance in depressive disorder. Metabolism 2000; 49:1145-1149
26. Sten-Linder M, Wedell A, Iselius L, Efendic S, Luff R, Luthman H.DNA polymorphisms in the human tyrosine hydroxylase/insulin/insulinlike growth factor II chromosomal region in relation to glucose and insulin responses. Diabetologia 1993; 36: 25-32
27. Tejedor-Real P, Faucon Biguet N, Dumas S, Mallet J.Tyrosine hydroxylase mRNA and proteinare down-regulated by chronic clozapine in both the mesocortîcolimbic and the nigrostritial systems. J Neurosci Res 2003; 72:105-115
28. Kaneda Y, Fujii A, Ohrnori T. The hypothalamic-pituitary-adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(5): 935-938
29. Andrews RCR. Diabetes and schizophrenia: genes or zinc deficiency. Lancet 1992; 340:1160
30. Ryan MCM, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002; 71: 239-257
31. Sneed KB, Gonzalez EC. Type 2 Diabetes mellitus induced by an atypical antipsychotic medication, JABFP May-June 2003; 16: 251
32. Gianfrancesco F, White R, Wang RH, Nasrallah HA.Antipsychoticinduced type 2 diabetes: Evidence from a large health plan database, J Clin Psychoparmacol, August 2003; 23: 328-329
33. Goudie AJ, Halford JC, Dovey TM, Cooper GD, Neill JC.H1- histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28: 2209
34. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger PJayathilake K, Meltzer HY, Roth BLHl-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-526
35. Tecott LH., LM Sun, SF Akana, AM Strack, DH Lowenstein. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995; 374: 542-546
36. T. Fujisawa H. Ikegami, E. Yamato K. Takekawa, Y. Nakagawa, Y. Hamada T. Ogal, H. Ueda, M. Shintani, M. Fukuda and T. Ogihara. Association of Trp64Arg mutation of the beta3-adrenergicreceptor with NIDDM and body weight gain. Diabetologia 1996; 39: 349-352
37. Shayegan DK, Stahl SM. Atypical antipsychotics:matching reseptör profile to individual patient's clinical profile. CNS Spectr 2004; 9: 6-14
38. Brömel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, Krieg JC, Hebebrand J. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998; 3: 76-80
39. Hagg S, Söderberg S, Ahren B, Olsson T, Mjörndal T.Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry 2001; 62: 843-848.
40. Pijl H. Reduced dopaminergic tone in hypothalamic neural circuits: expression of a " thrifty" genotype underlying the metabolic syndrome? Eur J Pharmacol, 7 November 2003; 480:125-131
41. Birkâs Kovâts D, Palik E, Faludi G, Cseh K.Possible connection between ghrelin, resistin and TNF - alpha levels and metabolic syndrome caused by atypical antipsychotics. Neuropsychopharmacologia Hungarica, Sep 2005; 7:132-139
42. Jin H, Meyer JM, Jeste DV.Atypical antipsychotics and glucose dysregulation: asystematic review, Schizophr Res, 2004; 1-18
43. International Diabetes Federation Metobolic Syndrome Concensus, Berlin 2005.
44. Expert Panel. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 2001; 285: 2486-2497
45. K Altınbaş, E Kurt, ET Oral, ikinci kuşak antipsikotiklerin endokrin yan etkileri: İstisna mı, kural mı?, Anadolu Psikiyatri Dergisi, 2005; 6: 259-266
46. Newcomer JW, Nasrallah HA, Loebel AD.The atypical therapy and metabolic issues and national survey: practice patterns and kowledge of psychiatrists. J Clin Psychophar-macol. 2004; 24(suppl 1): 1-6
47. Schatzberg AF, Nemeroff CB. Treatment of schizophrenia, weight gain, diabetes, and hiperlipidemia, Textbook of Psychopharmacology, The American Psychiatric Publishing, Third Edition, 2004; 897-898
48. Hedenmalm K, Hâgg S,- Stâhl M, Mortimer O, Spigset O.Glucose intolerance with atypical antipsychotics. Drug safety, 2002; 25: 1107-1116
49. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC.The effects of novel antipsychotics on glucose and lipid levels, J. Clin Psychiatry, 2002; 63: 856-865
50. Jin H, Meyer JM, Jeste DV.Phenpmenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann. Clin. Psychiatry, 2002; 14: 59-64
51. A. E. Danacı, S. Mızrak, Z. Hekimsoy, i. içelli. Olanzapin'e bağlı diabetes mellitus: Bir olgu sunumu. Klinik Psikofarmakoloji Bülteni, 2003; 13: 94-96
52. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differantial effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry, 2002; 63: 920-930
53. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, KeefeRS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical AntipsychoticTrials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, N Engl J Med, 2005; 353: 1209-1223
54. Gianfrancesco F, Grogg A, Mahmoud R, Wang RH, Meletiche D.Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin. Ther. 2003; 25:1150-1171
55. Cohen D, Stolk RP, Grobbee DE, Gispen-de Wied CC.Hiperglycemia and Diabetes in Patients with Schizophrenia or Schizoaffective Disorders, Diabetes Care, 2006; 29: 786
56. Reddymasu S, Bahta E, Levine S, Manas K, Slay LE.Elevated lipase and diabetic ketoacidosis associated with aripiprazole, JOP. 2006; 7: 303-305
57. Church CO, Stevens DL, Fugate SE.Diabetic ketoacidosis associated with aripiprazole, Diabet Med. 2005; 22:1440-1443
58. Sertöz ÖÖ, Mete HE. Obezite tedavisinde bilişsel davranışçı grup terapisinin kilo verme, yaşam kalitesi ve psikopatolojiye etkileri: sekiz haftalık izlem çalışması. Klinik Psikofarmakoloji Bülteni, 2005; 15:119-126

APA	USTA E, metin ö, BİRSÖZ S (2007). Şizofreni ve diyabet: Yeni kuşak antipsikotiklerin yol açtığı diyabet veya metabolik sendrom. , 207 - 216.
Chicago	USTA Evrim,metin özmen,BİRSÖZ Sunar Şizofreni ve diyabet: Yeni kuşak antipsikotiklerin yol açtığı diyabet veya metabolik sendrom. (2007): 207 - 216.
MLA	USTA Evrim,metin özmen,BİRSÖZ Sunar Şizofreni ve diyabet: Yeni kuşak antipsikotiklerin yol açtığı diyabet veya metabolik sendrom. , 2007, ss.207 - 216.
AMA	USTA E,metin ö,BİRSÖZ S Şizofreni ve diyabet: Yeni kuşak antipsikotiklerin yol açtığı diyabet veya metabolik sendrom. . 2007; 207 - 216.
Vancouver	USTA E,metin ö,BİRSÖZ S Şizofreni ve diyabet: Yeni kuşak antipsikotiklerin yol açtığı diyabet veya metabolik sendrom. . 2007; 207 - 216.
IEEE	USTA E,metin ö,BİRSÖZ S "Şizofreni ve diyabet: Yeni kuşak antipsikotiklerin yol açtığı diyabet veya metabolik sendrom." , ss.207 - 216, 2007.
ISNAD	USTA, Evrim vd. "Şizofreni ve diyabet: Yeni kuşak antipsikotiklerin yol açtığı diyabet veya metabolik sendrom". (2007), 207-216.

APA	USTA E, metin ö, BİRSÖZ S (2007). Şizofreni ve diyabet: Yeni kuşak antipsikotiklerin yol açtığı diyabet veya metabolik sendrom. Klinik Psikofarmakoloji Bülteni, 17(4), 207 - 216.
Chicago	USTA Evrim,metin özmen,BİRSÖZ Sunar Şizofreni ve diyabet: Yeni kuşak antipsikotiklerin yol açtığı diyabet veya metabolik sendrom. Klinik Psikofarmakoloji Bülteni 17, no.4 (2007): 207 - 216.
MLA	USTA Evrim,metin özmen,BİRSÖZ Sunar Şizofreni ve diyabet: Yeni kuşak antipsikotiklerin yol açtığı diyabet veya metabolik sendrom. Klinik Psikofarmakoloji Bülteni, vol.17, no.4, 2007, ss.207 - 216.
AMA	USTA E,metin ö,BİRSÖZ S Şizofreni ve diyabet: Yeni kuşak antipsikotiklerin yol açtığı diyabet veya metabolik sendrom. Klinik Psikofarmakoloji Bülteni. 2007; 17(4): 207 - 216.
Vancouver	USTA E,metin ö,BİRSÖZ S Şizofreni ve diyabet: Yeni kuşak antipsikotiklerin yol açtığı diyabet veya metabolik sendrom. Klinik Psikofarmakoloji Bülteni. 2007; 17(4): 207 - 216.
IEEE	USTA E,metin ö,BİRSÖZ S "Şizofreni ve diyabet: Yeni kuşak antipsikotiklerin yol açtığı diyabet veya metabolik sendrom." Klinik Psikofarmakoloji Bülteni, 17, ss.207 - 216, 2007.
ISNAD	USTA, Evrim vd. "Şizofreni ve diyabet: Yeni kuşak antipsikotiklerin yol açtığı diyabet veya metabolik sendrom". Klinik Psikofarmakoloji Bülteni 17/4 (2007), 207-216.